While the spine market has been in the doldrums since late 2010 when 20% of spine procedures were wiped out by payor pushback, there may be a lot more going on in this $7 billion global market than initially meets the eye. (See Also see "Spine Market Dx: Increasing Pain and Instability" - Medtech Insight, 1 December, 2010. and Also see "Beyond INFUSE: Spine Community Searches For Answers, Alternatives" - Medtech Insight, 1 September, 2011..) In less than a month, the US Food and Drug Administration (FDA) has approved three spine Premarket Approval (PMA) applications – for Globus Medical Inc.’s SECURE-C and NuVasive Inc.’s PCM (both cervical disc replacements [CDRs]) and for Paradigm Spine LLC’s coflex Interlaminar Stabilization Device, a nonfusion device for treating lumbar stenosis. The last time a spine product received PMA approval was in 2009.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?